WO2020172686A1 - Variants de peptide amyloïde - Google Patents

Variants de peptide amyloïde Download PDF

Info

Publication number
WO2020172686A1
WO2020172686A1 PCT/US2020/019557 US2020019557W WO2020172686A1 WO 2020172686 A1 WO2020172686 A1 WO 2020172686A1 US 2020019557 W US2020019557 W US 2020019557W WO 2020172686 A1 WO2020172686 A1 WO 2020172686A1
Authority
WO
WIPO (PCT)
Prior art keywords
iapp
hlapp
seq
peptide
peptides
Prior art date
Application number
PCT/US2020/019557
Other languages
English (en)
Other versions
WO2020172686A9 (fr
Inventor
David MOFFET
Luiza NOGAJ
Original Assignee
Loyola Marymount University
Mount Saint Mary's University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loyola Marymount University, Mount Saint Mary's University filed Critical Loyola Marymount University
Priority to US17/428,615 priority Critical patent/US20220119468A1/en
Priority to JP2021549163A priority patent/JP2022521266A/ja
Priority to EP20759401.1A priority patent/EP3927725A4/fr
Priority to CN202080015845.1A priority patent/CN113614101A/zh
Publication of WO2020172686A1 publication Critical patent/WO2020172686A1/fr
Publication of WO2020172686A9 publication Critical patent/WO2020172686A9/fr
Priority to IL285699A priority patent/IL285699A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La présente invention concerne des peptides IAPP qui inhibent l'agrégation de polypeptide amyloïde d'îlot humain et leur utilisation pour inhiber la formation de fibrilles amyloïdes.
PCT/US2020/019557 2019-02-22 2020-02-24 Variants de peptide amyloïde WO2020172686A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US17/428,615 US20220119468A1 (en) 2019-02-22 2020-02-24 Amyloid peptide variants
JP2021549163A JP2022521266A (ja) 2019-02-22 2020-02-24 アミロイドペプチドバリアント
EP20759401.1A EP3927725A4 (fr) 2019-02-22 2020-02-24 Variants de peptide amyloïde
CN202080015845.1A CN113614101A (zh) 2019-02-22 2020-02-24 淀粉样肽的变体
IL285699A IL285699A (en) 2019-02-22 2021-08-18 Amyloid peptide variants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962809167P 2019-02-22 2019-02-22
US62/809,167 2019-02-22

Publications (2)

Publication Number Publication Date
WO2020172686A1 true WO2020172686A1 (fr) 2020-08-27
WO2020172686A9 WO2020172686A9 (fr) 2020-11-12

Family

ID=72145021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/019557 WO2020172686A1 (fr) 2019-02-22 2020-02-24 Variants de peptide amyloïde

Country Status (6)

Country Link
US (1) US20220119468A1 (fr)
EP (1) EP3927725A4 (fr)
JP (1) JP2022521266A (fr)
CN (1) CN113614101A (fr)
IL (1) IL285699A (fr)
WO (1) WO2020172686A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814600A (en) * 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
WO2018144671A1 (fr) * 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Polypeptides à îlots amyloïdes mutants présentant une solubilité améliorée et leurs procédés d'utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
MXPA04010255A (es) * 2002-04-19 2008-03-04 Univ Toronto Metodos inmunologicos y composiciones para el tratamiento de la enfermedad de alzheimier.
CA2516726A1 (fr) * 2003-03-18 2004-09-30 Applied Research Systems Ars Holding N.V. Inhibiteurs d'agregation d'amyline et utilisation desdits inhibiteurs
GB0501348D0 (en) * 2005-01-24 2005-03-02 Zyentia Ltd Compositions and methods
EP2010208A1 (fr) * 2006-03-31 2009-01-07 Amylin Pharmaceuticals, Inc. Amyline et agonistes d'amyline pour traiter les maladies et troubles psychiatriques
EP2036923A1 (fr) * 2007-09-11 2009-03-18 Novo Nordisk A/S Dérivés d'amyline améliorés
US20130022620A1 (en) * 2011-06-09 2013-01-24 Ann Marie Schmidt Assays and methods pertaining to pre-amyloid intermediates
RU2669999C2 (ru) * 2011-06-10 2018-10-17 Ново Нордиск А/С Полипептиды
WO2014041069A1 (fr) * 2012-09-12 2014-03-20 Neurimmune Holding Ag Anticorps spécifiques du polypeptide amyloïde des îlots humains (hiapp) et leurs utilisations
WO2015062803A1 (fr) * 2013-10-29 2015-05-07 Kapurniotu Aphrodite Segments modifiés de polypeptide amyloïde des îlots
CN108070075A (zh) * 2016-11-09 2018-05-25 可口可乐公司 生物基meg和聚酯纤维组合物以及制造它们的方法
SG11202012091WA (en) * 2018-06-15 2021-01-28 Proclara Biosciences Inc General amyloid interaction motif (gaim)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814600A (en) * 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
WO2018144671A1 (fr) * 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Polypeptides à îlots amyloïdes mutants présentant une solubilité améliorée et leurs procédés d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEDDENRIEP BRADLEY ET AL.: "Short Peptides as Inhibitors of Amyloid Aggregation", OPEN BIOTECHNOL J., vol. 5, no. 1-17, 23 December 2011 (2011-12-23), pages 39 - 46, XP055049166, DOI: 10.2174/1874070701105010039 *
See also references of EP3927725A4 *

Also Published As

Publication number Publication date
EP3927725A4 (fr) 2023-06-14
EP3927725A1 (fr) 2021-12-29
CN113614101A (zh) 2021-11-05
IL285699A (en) 2021-10-31
WO2020172686A9 (fr) 2020-11-12
JP2022521266A (ja) 2022-04-06
US20220119468A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
US11141469B2 (en) Methods and compositions for treating aging-associated conditions
KR102508651B1 (ko) 신경계 및 신경변성 상태의 요법으로서 장기간 작용하는 glf-1r 작용제
US11738070B2 (en) Methods and compositions for improved cognition
KR20100113163A (ko) 알파 ７ 니코틴 작용제 및 항정신병제의 조합
JP2023082076A (ja) 糖尿病の処置のためのペプチド
WO2007123848A2 (fr) Préparations thérapeutiques contenant des protéines slrp de classe i modifiées
BR112019023116A2 (pt) fragmentos de cdnf e manf do terminal c, composições farmacêuticas que os compreendem e usos dos mesmos
JP2017505772A (ja) ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
US20220119468A1 (en) Amyloid peptide variants
Kelly et al. Neuronally Derived Soluble Abeta Evokes Cell-Wide Astrocytic Calcium Dysregulation in Absence of Amyloid Plaques in Vivo
JPWO2007139120A1 (ja) アミロイドβクリアランス促進剤
US20180044398A1 (en) Specific A-beta Species-Binding Peptides for the Therapy and/or Diagnosis of Alzheimer's Dementia
EP4252750A1 (fr) Conservation pharmaceutique de l'activation de creb dans le traitement de la maladie d'alzheimer
JP6455983B2 (ja) アミロイド分解能を有する人工ペプチドおよびその利用
BR112020019696A2 (pt) Fragmentos de cdnf e manf do terminal c, composições farmacêuticas que os compreendem e usos dos mesmos
Grochowska et al. A molecular mechanism by which amyloid-β induces inactivation of CREB in Alzheimer’s Disease
Zhao et al. Cardiac neurons expressing a glucagon-like receptor mediate cardiac arrhythmia induced by high-fat diet in Drosophila
JP2017149685A (ja) 造影剤の使用に関連して腎臓の保護に使用するためのα−１−ミクログロブリン
KR20230054440A (ko) 심근 손상의 치료 또는 예방에 사용하기 위한 펩타이드
Flores The Role of KCC3 in Neuronal Homeostasis
CN117881687A (zh) 多肽抑制剂及其用途
Brooke The classification of muscle diseases
WO2016060190A1 (fr) AGENT THÉRAPEUTIQUE DESTINÉ AU TROUBLE COGNITIF INDUIT PAR LA β-PROTÉINE AMYLOÏDE
Cardoso Dynamics of transthyretin fibrillogenesis: contribution to therapeutic approaches in familial amyloidotic polyneuropathy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20759401

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021549163

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020759401

Country of ref document: EP

Effective date: 20210922